Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
25
05
2024
accepted:
12
07
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
aheadofprint
Résumé
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a significant global health problem. In immunocompetent individuals, the microorganism can remain in a latent, non-contagious form, however, it may become active under conditions of immunosuppression. Tumour necrosis factor (TNF) inhibitors, which are frequently used for the management of immune-mediated disorders like psoriasis, have been associated with a significantly increased risk of reactivating latent TB. Consequently, international guidelines recommend TB screening and preventive treatment before starting anti-TNF therapy. These recommendations have extended to IL-12/23, IL-17, IL-23 and TYK2 inhibitors under a caution principle, despite their different mechanisms of action. However, current evidence suggests that some of these agents are arguably not associated with an increased risk of TB reactivation or development of TB disease after infection, which calls for a critical reassessment of these guidelines. We have conducted a literature search evaluating the risk of TB reactivation associated with these innovative therapies, integrating findings from both randomized clinical trials and real-world evidence. The identified evidence is limited but the low number of identified cases of reactivation with IL-17 and IL-23 inhibitors prompts reconsidering the need for preventive treatment for latent TB in all cases, regardless of biologic class or individual patient's risk of TB reactivation or drug toxicity. This review, along with the clinical insight of a panel of experts on behalf of the SPIN-FRT, led to the development of these consensus recommendations for managing psoriasis treatment in patients with latent TB infection or at risk of TB infection, who are receiving or are intended to receive biologic and non-biologic targeted therapies. These recommendations highlight the need for updates to the existing guidelines, aiming to provide a more differentiated approach that reflects the evolving landscape of psoriasis treatment and its implications for TB management.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondation René Touraine (FRT)
Informations de copyright
© 2024 European Academy of Dermatology and Venereology.
Références
Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–994.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315.
MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global epidemiology of tuberculosis and Progress toward achieving global targets—2017. MMWR Morb Mortal Wkly Rep. 2019;68(11):263–266.
Aiello A, Najafi‐Fard S, Goletti D. Initial immune response after exposure to mycobacterium tuberculosis or to SARS‐COV‐2: similarities and differences. Front Immunol. 2023;14:1244556.
Kock R, Michel AL, Yeboah‐Manu D, Azhar EI, Torrelles JB, Cadmus SI, et al. Zoonotic tuberculosis—the changing landscape. Int J Infect Dis. 2021;113(Suppl 1):S68–S72.
Cavalcanti YV, Brelaz MCA, de Andrade Lemoine Neves JK, Ferraz JC, Pereira VRA. Role of TNF‐alpha, IFN‐gamma, and IL‐10 in the development of pulmonary tuberculosis. Pulm Med. 2012;2012:745483.
Alsayed SSR, Gunosewoyo H. Tuberculosis: pathogenesis, current treatment regimens and new drug targets. Int J Mol Sci. 2023;24(6):5202.
Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. Int J Infect Dis. 2022;124(Suppl 1):S12–S19.
Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 2002;20:581–620.
Castro KG. Tuberculosis as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995;21(Suppl 1):S66–S71.
Goletti D, Pisapia R, Fusco FM, Aiello A, van Crevel R. Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes. Int J Tuberc Lung Dis. 2023;27(4):284–290.
Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5(2):e10.
WHO. Global tuberculosis report 2023. 2023.
Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a Re‐estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.
Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, et al. Risk of tuberculosis in patients treated with TNF‐alpha antagonists: a systematic review and meta‐analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567.
Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509.
Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47–55.
Miller EA, Ernst JD. Anti‐TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest. 2009;119(5):1079–1082.
Souto A, Maneiro JR, Salgado E, Carmona L, Gomez‐Reino JJ. Risk of tuberculosis in patients with chronic immune‐mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta‐analysis of randomized controlled trials and long‐term extension studies. Rheumatology (Oxford). 2014;53(10):1872–1885.
Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: a meta‐analysis. Exp Ther Med. 2016;12(3):1693–1704.
Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Massafra U, Baldi G, et al. Characterization of QuantiFERON‐TB‐plus results in latent tuberculosis infected patients with or without immune‐mediated inflammatory diseases. J Infect. 2019;79(1):15–23.
Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther. 2018;16(6):501–512.
Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence‐based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2015;73(3):420–428. e1.
Diel R, Schaberg T, Nienhaus A, Otto‐Knapp R, Kneitz C, Krause A, et al. Joint statement (DZK, DGRh, DDG) on the tuberculosis risk with treatment using novel non‐TNF‐alpha biologicals. Pneumologie. 2021;75(4):293–303.
Rodriguez‐Jimenez P, Mir‐Viladrich I, Chicharro P, Solano‐López G, López‐Longo FJ, Taxonera C, et al. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: a multidisciplinary consensus statement adapted to the dermatology patient. Actas Dermosifiliogr (Engl Ed). 2018;109(7):584–601.
WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018 Geneva.
Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1–11.
Denholm JT, McBryde E, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145–149.
Lee SH, Yim J‐J, Kim HJ, Shim TS, Seo HS, Cho YS, et al. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect. 2012;140(6):1028–1035.
Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi‐Furst F, et al. National consensus statement by the Austrian societies for rheumatology, pulmonology, Infectiology, dermatology and gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs). Z Rheumatol. 2023;82(2):163–174.
Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus kinases. Expert Opin Drug Saf. 2020;19(7):861–872.
Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel‐Moreno J, Cilley GE, et al. IL‐23 and IL‐17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during mycobacterium tuberculosis challenge. Nat Immunol. 2007;8(4):369–377.
Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, Kishihara K, et al. Essential role of IL‐17A in the formation of a mycobacterial infection‐induced granuloma in the lung. J Immunol. 2010;184(8):4414–4422.
Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley‐Gibbs DM, et al. IL‐23 compensates for the absence of IL‐12p70 and is essential for the IL‐17 response during tuberculosis but is dispensable for protection and antigen‐specific IFN‐gamma responses if IL‐12p70 is available. J Immunol. 2005;175(2):788–795.
Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol. 2007;19(6):377–382.
Segueni N, Jacobs M, Ryffel B. Innate type 1 immune response, but not IL‐17 cells control tuberculosis infection. Biom J. 2021;44(2):165–171.
Segueni N, Tritto E, Bourigault ML, Rose S, Erard F, le Bert M, et al. Controlled mycobacterium tuberculosis infection in mice under treatment with anti‐IL‐17A or IL‐17F antibodies, in contrast to TNFalpha neutralization. Sci Rep. 2016;6:36923.
Arbues A, Brees D, Chibout S‐D, Fox T, Kammüller M, Portevin D. TNF‐alpha antagonists differentially induce TGF‐beta1‐dependent resuscitation of dormant‐like mycobacterium tuberculosis. PLoS Pathog. 2020;16(2):e1008312.
Kammuller M, Tsai T‐F, Griffiths CE, Kapoor N, Kolattukudy PE, Brees D, et al. Inhibition of IL‐17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol. 2017;6(8):e152.
Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin‐17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1449–1456.
Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis—time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824–834.
Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43–51.
Gottlieb AB, Deodhar A, Mcinnes IB, Baraliakos X, Reich K, Schreiber S, et al. Long‐term safety of Secukinumab over five years in patients with moderate‐to‐severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post‐marketing surveillance data. Acta Derm Venereol. 2022;102:adv00698.
Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2020;59(12):3834–3844.
Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, et al. Corrigendum to: safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2021;60(11):5485.
Mrowietz U, Riedl E, Winkler S, Xu W, Patel H, Agada N, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: a report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol. 2020;83(5):1436–1439.
Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long‐term safety of secukinumab in patients with moderate‐to‐severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post‐marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.
van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023;82(4):515–526.
Baraliakos X, Deodhar A, Dougados M, Gensler LS, Molto A, Ramiro S, et al. Safety and efficacy of Bimekizumab in patients with active ankylosing spondylitis: three‐year results from a phase IIb randomized controlled trial and its open‐label extension study. Arthritis Rheumatol. 2022;74(12):1943–1958.
Coates LC, McInnes IB, Merola JF, Warren RB, Kavanaugh A, Gottlieb AB, et al. Safety and efficacy of Bimekizumab in patients with active psoriatic arthritis: three‐year results from a phase IIb randomized controlled trial and its open‐label extension study. Arthritis Rheumatol. 2022;74(12):1959–1970.
Fiorella C. Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: a multi‐case report analysis. Clin Case Rep. 2022;10(1):e05302.
Galluzzo M, D'Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real‐life analysis after 136 weeks of treatment with secukinumab in moderate‐to‐severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173–182.
Lasagni C, Bigi L, Conti A, Pellacani G. Successful therapy of plaque‐type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. J Dermatolog Treat. 2018;29(sup2):5–8.
Liu S, He Z, Wu W, Jin H, Cui Y. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection. Clin Rheumatol. 2023;42(9):2369–2376.
Machado A, Abreu M, Torres T. Safety of secukinumab in psoriasis patients with latent tuberculosis infection. Eur J Dermatol. 2020;30(6):740–741.
Manzanares N, Vilarrasa E, López A, Alonso ML, Velasco M, Riera J, et al. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: multicenter case series of 35 patients. J Eur Acad Dermatol Venereol. 2023;38(1):e26–e28.
Mastorino L, Dapavo P, Trunfio M, Avallone G, Rubatto M, Calcagno A, et al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary Care Centre in Northern Italy. Acta Derm Venereol. 2022;102:adv00821.
Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Foti C, et al. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real‐world setting of latent tuberculosis infection. J Dermatolog Treat. 2022;33(5):2629–2633.
Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and safety of Secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol. 2019;11(Suppl 1):23–28.
Shu D, Zhang Z, Zhou EY, Ma X, Zhao Y. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL‐17 inhibitors? A cohort study. Dermatol Ther. 2020;33(6):e14512.
Xiao Y, Mi W, Wang J, Wen D, Wang Y, Gu Y, et al. A propensity score‐matched study on the changes of TB status and TB‐IGRA values in patients with psoriasis with latent TB receiving Secukinumab. Dermatol Ther (Heidelb). 2023;13(10):2387–2401.
Torres T, Chiricozzi A, Puig L, Lé AM, Marzano AV, Dapavo P, et al. Treatment of psoriasis patients with latent tuberculosis using IL‐17 and IL‐23 inhibitors: a retrospective, multinational, multicentre study. Am J Clin Dermatol. 2024;25:333–342.
He CX, Wu C, Zhang L, Jin HZ. Interleukin‐17A inhibitors in patients with psoriasis and tuberculosis infection: a 2‐year prospective study on safety without preventive treatment. Dermatol Ther (Heidelb). 2024;14:893–906.
Gaffen SL, Jain R, Garg AV, Cua DJ. The IL‐23‐IL‐17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600.
Shen H, Chen ZW. The crucial roles of Th17‐related cytokines/signal pathways in M. tuberculosis infection. Cell Mol Immunol. 2018;15(3):216–225.
Blauvelt A, Chiricozzi A, Ehst BD, Lebwohl MG. Safety of IL‐23 p19 inhibitors for the treatment of patients with moderate‐to‐severe plaque psoriasis: a narrative review. Adv Ther. 2023;40(8):3410–3433.
Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non‐anti‐TNF‐targeted biologics. Mediators Inflamm. 2017;2017:8909834.
Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf. 2020;19(1):69–82.
Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, et al. Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–475.
Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, et al. Long‐term safety of Guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2023;47:39–57.
Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, et al. Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615–622.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, et al. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double‐blind GALAXI‐1 trial. Lancet Gastroenterol Hepatol. 2024;9(2):133–146.
Peyrin‐Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KH(G), et al. Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology. 2023;165(6):1443–1457.
Gao X, Fujii T, Ye BD, Chou JW, Sugimoto K, Cao Q, et al. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Gastroenterol Hepatol. 2024;39(1):55–65.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double‐blind, placebo‐controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031–2046.
Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, et al. Long‐term safety and efficacy of Risankizumab treatment in patients with Crohn's disease: results from the phase 2 open‐label extension study. J Crohns Colitis. 2021;15(12):2001–2010.
Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, et al. Efficacy and safety of continuous Risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658.
Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, et al. Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol. 2020;34(8):1744–1749.
Kearney N, Byrne N, Kirby B, Hughes R. Successful use of guselkumab in the treatment of severe hidradenitis suppurativa. Clin Exp Dermatol. 2020;45(5):618–619.
Motolese A, Ceccarelli M, Macca L, Li Pomi F, Ingrasciotta Y, Nunnari G, et al. Novel therapeutic approaches to psoriasis and risk of infectious disease. Biomedicine. 2022;10(2):228.
Cooper AM, Solache A, Khader SA. Interleukin‐12 and tuberculosis: an old story revisited. Curr Opin Immunol. 2007;19(4):441–447.
Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate‐to‐severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145–1152.
Ghosh S, Feagan BG, Ott E, Gasink C, Godwin B, Marano C, et al. Safety of Ustekinumab in inflammatory bowel disease: pooled safety analysis through 5 years in Crohn's disease and 4 years in ulcerative colitis. J Crohns Colitis. 2024;18:1091–1101.
Tsai TF, Chiu HY, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol. 2013;168(2):444–446.
Cho SI, Kang S, Kim YE, Lee JY, Jo SJ. Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea. J Am Acad Dermatol. 2020;82(5):1243–1245.
Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol. 2014;24(4):508–509.
Lynch M, Roche L, Horgan M, Ahmad K, Hackett C, Ramsay B. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017;3(3):230–232.
Renoux MC, Dutronc S, Kollen L, Theret S, Moreau J. A case of disseminated tuberculosis in a child with Crohn's disease after treatment with Azathioprine, Adalimumab and Ustekinumab. Arch Bronconeumol. 2021;57(8):552–554.
Tominaga K, Tanaka T, Kanazawa M, Watanabe S, Nemoto R, Abe K, et al. A case of Crohn's disease with cardiac tamponade caused by tuberculous pericarditis: assessment of a rare phenomenon. Healthcare (Basel). 2021;9(6):695.
Torres T, Puig L. Apremilast: a novel Oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23–32.
Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, et al. Long‐term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >/=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–317. e1.
Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz‐González F, van den Bosch F, et al. A phase III, randomized, controlled trial of Apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724–1734.
Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065–1073.
Kavanaugh A, Mease PJ, Gomez‐Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo‐controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026.
Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, et al. Apremilast monotherapy in DMARD‐naive psoriatic arthritis patients: results of the randomized, placebo‐controlled PALACE 4 trial. Rheumatology (Oxford). 2018;57(7):1253–1263.
Abignano G, Fadl N, Merashli M, Wenham C, Freeston J, McGonagle D, et al. Apremilast for the treatment of active psoriatic arthritis: a single‐centre real‐life experience. Rheumatology (Oxford). 2018;57(3):578–580.
Favalli EG, Conti F, Selmi C, Iannone F, Bucci R, D'Onofrio F, et al. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. Clin Exp Rheumatol. 2020;38(1):19–26.
Hagberg KW, Persson R, Vasilakis‐Scaramozza C, Niemcryk S, Peng M, Paris M, et al. Herpes zoster, hepatitis C, and tuberculosis risk with Apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis. Clin Epidemiol. 2020;12:153–161.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52‐week, randomized, double‐blinded, placebo‐controlled phase 3 POETYK PSO‐1 trial. J Am Acad Dermatol. 2023;88(1):29–39.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52‐week, randomized, double‐blinded, phase 3 program fOr evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51.
Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate‐to‐severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023;8(4):156–165.